keyword
MENU ▼
Read by QxMD icon Read
search

Urothelial cell carcinoma

keyword
https://www.readbyqxmd.com/read/29342309/prognostic-power-of-a-tumor-differentiation-gene-signature-for-bladder-urothelial-carcinomas
#1
Qianxing Mo, Fotis Nikolos, Fengju Chen, Zoe Tramel, Yu-Cheng Lee, Kazukuni Hayashi, Jing Xiao, Jianjun Shen, Keith Syson Chan
Background: Muscle-invasive bladder cancers (MIBCs) cause approximately 150 000 deaths per year worldwide. Survival for MIBC patients is heterogeneous, with no clinically validated molecular markers that predict clinical outcome. Non-MIBCs (NMIBCs) generally have favorable outcome; however, a portion progress to MIBC. Hence, development of a prognostic tool that can guide decision-making is crucial for improving clinical management of bladder urothelial carcinomas. Methods: Tumor grade is defined by pathologic evaluation of tumor cell differentiation, and it often associates with clinical outcome...
January 12, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29341833/immune-modified-response-evaluation-criteria-in-solid-tumors-imrecist-refining-guidelines-to-assess-the-clinical-benefit-of-cancer-immunotherapy
#2
F Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean-Charles Soria, Mizuki Nishino, Josep Tabernero, Thomas Powles, David Smith, Axel Hoos, Chris McKenna, Ulrich Beyer, Ina Rhee, Gregg Fine, Nathan Winslow, Daniel S Chen, Jedd D Wolchok
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. Modifications to imRECIST versus RECIST v1...
January 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29333509/rate-and-association-of-lower-urinary-tract-infection-with-recurrence-after-transurethral-resection-of-bladder-tumor
#3
Byung Soo Kim, Bum Sik Tae, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Chang Wook Jeong
Purpose: To evaluate the rate of pyuria and bacteriuria after transurethral resection of bladder tumor (TURBT). Materials and Methods: We retrospectively evaluated data obtained from 363 patients who underwent TURBT between October 2012 and December 2013 at Seoul National University Hospital. Urinalysis and urine culture were assessed at 3, 6, 12, and 24 months postoperatively. Primary endpoint was the rate of bacteriuria (≥105/mL in a midstream) and pyuria (white blood cells ≥5/high-power field)...
January 2018: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/29330759/-autoimmune-reactions-to-immune-checkpoint-inhibitors
#4
REVIEW
W Pönisch, R Alten, C Baerwald
Immune checkpoint inhibitors (ICI) have dramatically changed the face of cancer treatment and are gaining in importance. The ICIs have now been approved for the treatment of advanced cancers, including melanoma, non-small-cell and small cell lung cancers, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancers and urothelial carcinoma and further indications are to be expected. The organs most affected by an autoimmune reaction are the intestines, the musculoskeletal system, skin, endocrine organs, the liver and the lungs...
October 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/29328452/hif%C3%A2-1%C3%AE-%C3%A2-induced-upregulation-of-lncrna-uca1-promotes-cell-growth-in-osteosarcoma-by-inactivating-the-pten-akt-signaling-pathway
#5
Tengfei Li, Yang Xiao, Tunsheng Huang
Increasing evidence indicates that long non‑coding RNAs (lncRNAs) play an important role in multiple biological processes including cell growth, differentiation, proliferation and invasion. Urothelial carcinoma associated 1 (UCA1) is a highly conserved nuclear ncRNA and a key regulator of cell proliferation and apoptosis in several types of cancers. However, its role in osteosarcoma progression is not well known. In the present study, we aimed to determine the biological role of UCA1 in osteosarcoma progression...
January 3, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29325739/anti-programmed-cell-death-1-ligand-1-pd-1-pd-l1-antibodies-for-the-treatment-of-urothelial-carcinoma-state-of-the-art-and-future-development
#6
REVIEW
Thomas Powles, Andrea Necchi, Galit Rosen, Subramanian Hariharan, Andrea B Apolo
Immunotherapy with programmed cell death 1/ligand 1 (PD-1/PD-L1) checkpoint inhibitors has expanded a previously limited pool of effective treatment options for patients with metastatic urothelial carcinoma, particularly those with recurring or refractory disease and those who are ineligible for cisplatin. This review reports key findings from completed and ongoing clinical trials that highlight the potential of PD-1/PD-L1 blockade in urothelial carcinoma. A literature search was performed of PubMed, Embase, ClinicalTrials...
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29323063/evaluation-of-muc1-and-p53-expressions-in-noninvasive-papillary-urothelial-neoplasms-of-bladder-their-relationship-with-tumor-grade-and-role-in-the-differential-diagnosis
#7
Esin Kaymaz, Elif Ozer, Hatice Unverdi, Sema Hucumenoglu
PURPOSE: The aim of this study was to investigate the usability of MUC1 and p53 for differential diagnosis of noninvasive papillary urothelial neoplasias, especially for distinguishing papillary urothelial neoplasm of low malignant potential (PUNLMP) from low-grade papillary urothelial carcinoma (LGPUC) when the histologic signs are not obvious. MATERIALS AND METHODS: Seventeen biopsy specimens of the patients with PUNLMP, 20 with LGPUC and 13 with high-grade papillary urothelial carcinoma (HGPUC) were stained for MUC1 and p53 protein by immunohistochemical methods...
October 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29312470/combined-inhibition-of-bet-proteins-and-class-i-hdacs-synergistically-induces-apoptosis-in-urothelial-carcinoma-cell-lines
#8
Alexander S Hölscher, Wolfgang A Schulz, Maria Pinkerneil, Günter Niegisch, Michèle J Hoffmann
Background: New efficient therapies for urothelial carcinoma (UC) are urgently required. Small-molecule drugs targeting chromatin regulators are reasonable candidates because these regulators are frequently mutated or deregulated in UC. Indeed, in previous work, Romidepsin, which targets class I histone deacetylases (HDAC), efficiently killed UC cells, but did not elicit canonical apoptosis and affected benign urothelial cells indiscriminately. Combinations of HDAC inhibitors with JQ1, an inhibitor of bromodomain-containing acetylation reader proteins like BRD4, which promote especially the transcription of pro-tumorigenic genes, have shown efficacy in several tumor types...
2018: Clinical Epigenetics
https://www.readbyqxmd.com/read/29311157/nkx2-8-inhibits-epithelial-mesenchymal-transition-in-bladder-urothelial-carcinoma-via-transcriptional-repression-of-twist1
#9
Chunping Yu, Zhuowei Liu, Qiuhong Chen, Yonghong Li, Lijuan Jiang, Zhiling Zhang, Fangjian Zhou
Epithelial-to-mesenchymal transition (EMT) promotes metastasis which is the main cause of bladder urothelial carcinoma (UC)-related death. Loss of the candidate tumor suppressor gene Nkx2.8 has been associated with UC lymph node metastasis. Here we show that enforced expression of Nkx2.8 is sufficient to inhibit EMT, reduce motility and blunt invasiveness of UC cells. Mechanistic investigations showed that Nkx2.8 negatively regulated expression of the EMT inducer Twist1 in UC cells, at both the level of mRNA and protein accumulation...
January 8, 2018: Cancer Research
https://www.readbyqxmd.com/read/29290331/-atezolizumab-tecentriq%C3%A2-activity-indication-and-modality-of-use-in-advanced-or-metastatic-urinary-bladder-carcinoma
#10
Alice Bernard-Tessier, Clément Bonnet, Pernelle Lavaud, Marco Gizzi, Yohann Loriot, Christophe Massard
Treatments for patients with metastatic or advanced urothelial carcinomas on progression after first line chemotherapy or unfit for cisplatin are currently limited. Atezolizumab (Tecentriq®) is a monoclonal antibody targeting PD-L1. The first of IMVIGOR 210 phase II trial (NCT02951767) investigated atezolizumab as front line treatment among 119 patients with metastatic urothelial cancer unfit for cisplatin. Response rate was 23% and median overall survival 15.9 months. The second cohort (NCT02108652) included 310 patients whose tumors were progressing after first line platinum-based chemotherapy...
December 28, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/29285224/soluble-chemokine-c-x-c-motif-ligand-16-cxcl16-in-urine-as-a-novel-biomarker-candidate-to-identify-high-grade-and-muscle-invasive-urothelial-carcinomas
#11
Kerstin Lang, Nadine Bonberg, Sibylle Robens, Thomas Behrens, Jan Hovanec, Thomas Deix, Katharina Braun, Florian Roghmann, Joachim Noldus, Volker Harth, Karl-Heinz Jöckel, Raimund Erbel, Yu Chun Tam, Andrea Tannapfel, Heiko Udo Käfferlein, Thomas Brüning
Information on biomarkers of urothelial carcinomas (UC) for clinical decision-making is limited. Here, we newly identified and verified CXCL16 as a promising novel biomarker in urine for high grade and muscle invasive UC in a cross-sectional cohort of 308 UC patients, 126 urological hospital controls, and 50 population controls using antibody arrays and ELISA. Median CXCL16 levels in urine was significantly higher in UC patients (273.2 pg/mg creatinine) compared to hospital (148.1 pg/mg) and population controls (85...
December 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/29279584/immunohistochemical-expression-of-nanog-in-urothelial-carcinoma-of-the-bladder
#12
M K A Md Akhir, H Hussin, A Veerakumarasivam, C S Choy, M A Abdullah, F Abd Ghani
Urothelial carcinoma is a common malignant neoplasm that has a poor prognosis and a high frequency of recurrence and metastasis. Constant disease surveillance with periodic and long term cystoscopy examination is necessary for management of the disease. However, the monitoring and therapy regimen is expensive, incurring a massive burden to patients and the government. Therefore, the development of specific biomarkers for urothelial carcinoma at an early stage and recurrence detection becomes a priority. Homeobox genes are a family of genes that are involved in tumourigenesis...
December 2017: Malaysian Journal of Pathology
https://www.readbyqxmd.com/read/29278461/implementing-the-paris-system-for-reporting-urinary-cytology-results-in-a-decrease-in-the-rate-of-the-atypical-category-and-an-increase-in-its-prediction-of-subsequent-high-grade-urothelial-carcinoma
#13
Yujing Wang, Manon Auger, Yonca Kanber, Derin Caglar, Fadi Brimo
BACKGROUND: In the current study, the authors evaluated the impact of implementing The Paris System for Reporting Urinary Cytology (PSRUC) on the prevalence of various cytological categories and their association with a subsequent diagnosis of high-grade urothelial carcinoma (HGUC). METHODS: A comparative study was conducted over the 6-month period before PSRUC implementation (2013), including 1653 patients and 2371 specimens versus a 6-month period after implementation of the PSRUC (2016), including 1478 patients and 2392 specimens...
December 26, 2017: Cancer
https://www.readbyqxmd.com/read/29277583/wisp1-genetic-variants-as-predictors-of-tumor-development-with-urothelial-cell-carcinoma
#14
Hsiang-Lin Lee, Hui-Ling Chiou, Shian-Shiang Wang, Sheng-Chun Hung, Ming-Chih Chou, Shun-Fa Yang, Ming-Ju Hsieh, Ying-Erh Chou
OBJECTIVES: Urothelial cell carcinoma (UCC) of the urinary bladder is a major malignancy of the genitourinary tract. Etiological factors, such as the environment, ethnicity, genetics, and diet, contribute to UCC carcinogenesis. WNT1-inducible signaling pathway protein 1 (WISP1), also known as CCN4, a cysteine-rich protein belonging to the Cyr61, CTGF, Nov (CCN) family of matricellular proteins, has many developmental functions and might be involved in carcinogenesis. This study investigated WISP1 single-nucleotide polymorphisms to evaluate UCC susceptibility and clinicopathological characteristics...
December 22, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29276062/targeting-urothelial-carcinoma-cells-by-combining-cisplatin-with-a-specific-inhibitor-of-the-autophagy-inducing-class-iii-ptdins3k-complex
#15
David Schlütermann, Margaretha A Skowron, Niklas Berleth, Philip Böhler, Jana Deitersen, Fabian Stuhldreier, Nora Wallot-Hieke, Wenxian Wu, Christoph Peter, Michèle J Hoffmann, Günter Niegisch, Björn Stork
BACKGROUND: Cisplatin-based regimens are routinely employed for the treatment of urothelial carcinoma. However, therapeutic success is hampered by the primary presence of or the development of cisplatin resistance. This chemoresistance is executed by multiple cellular pathways. In recent years, the cellular process of autophagy has been identified as a prosurvival pathway of cancer cells. On the one hand, autophagy enables cancer cells to survive conditions of low oxygen or nutrient supply, frequently found in tumors...
December 21, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29273405/re-molecular-classification-of-urothelial-carcinoma-global-mrna-classification-versus-tumour-cell-phenotype-classification
#16
Ralph Peeker
No abstract text is available yet for this article.
December 19, 2017: European Urology
https://www.readbyqxmd.com/read/29260622/surrogate-end-points-for-overall-survival-in-trials-of-pd-l-1-inhibitors-for-urinary-cancers-a-systematic-review
#17
Omar Abdel-Rahman
AIM: Numerous trials for PD-(L)1 inhibitors in the management of advanced urinary cancers (urothelial carcinoma and renal cell carcinoma) were published recently. It is not known exactly what should be the optimal surrogate end point for overall survival (OS) in this context. MATERIALS & METHODS: PubMed database and ASCO meeting library were searched till August 2017. Eligible studies included prospective clinical studies evaluating PD-(L)1 inhibitors for the management of advanced urothelial carcinoma or renal cell carcinoma...
February 2018: Immunotherapy
https://www.readbyqxmd.com/read/29259653/cytokeratin-20-p53-dual-immunocytochemistry-for-improving-the-diagnostic-accuracy-of-urine-liquid-based-cytology-in-the-detection-of-urothelial-neoplasm-a-retrospective-study
#18
Hyun-Jung Kim, Ji-Hyeong Yoo
Backgrounds: Dual immunocytochemistry (DIC) with cytokeratin (CK) 20 and p53 in liquid-based cytology is a tool for improving the accuracy of urine cytology (UC). This study was conducted to compare the diagnostic accuracy of UC alone with that of UC combined with CK20/p53 DIC. Methods: We retrieved urine samples collected between January 2015 and March 2016 stored in PreservCyt®solution that were from cases categorized as malignant, highly suspicious, suspicious, and atypical and that were matched with a subsequent biopsy...
2017: CytoJournal
https://www.readbyqxmd.com/read/29251368/the-paris-system-for-urine-cytology-in-upper-tract-urothelial-specimens-a-comparative-analysis-with-biopsy-and-surgical-resection
#19
X Zheng, Q Si, D Du, M Harshan, Z Zhang, K Haines, W Shi, D C Chhieng
INTRODUCTION: The Paris System (TPS) has recently been used in classification of urinary tract cytological specimens. Upper urinary tract (UUT) specimens are cytologically challenging. The utility of TPS was investigated in evaluating UUT specimens and its correlation with subsequent histological follow-up. METHOD: From 2014 to 2017, 324 cytology cases of UUT from 179 patients were retrieved. Concurrent or subsequent biopsy or resection within a 2-month period was available in 125 cases from 74 patients...
December 18, 2017: Cytopathology: Official Journal of the British Society for Clinical Cytology
https://www.readbyqxmd.com/read/29250474/the-most-recent-oncologic-emergency-what-emergency-physicians-need-to-know-about-the-potential-complications-of-immune-checkpoint-inhibitors
#20
REVIEW
Duncan Simmons, Eddy Lang
Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmable cell death protein 1 (PD-1)/PD-L1 have shown antitumor activity in cancers such as melanoma, non-small cell lung cancer, renal cell carcinoma, and urothelial cancer. Certain checkpoint inhibitors have been approved for use in Canada, and are becoming a mainstay in the treatment of melanoma and other malignancies. These drugs have a unique side effect profile and are known to cause immune-related adverse events (irAEs)...
October 13, 2017: Curēus
keyword
keyword
18910
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"